Biologic protease inhibitors as novel therapeutic agents

Biochimie

Volumn 92, Issue 11, 2010, Pages 1681-1688

  Scott, Christopher J ^a   Taggart, Clifford C ^b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Inhibitory antibody; Kunitz domain; Phage display; Propeptide

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIFIBRINOLYTIC AGENT; APROTININ; ASPARTIC PROTEINASE INHIBITOR; BEVACIZUMAB; CASPASE INHIBITOR; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; CATHEPSIN V; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DX 1000; DX 2300; DX 2400; ECALLANTIDE; ELAFIN; GELATINASE A; INFLIXIMAB; MATRIX METALLOPROTEINASE 14; MONOCLONAL ANTIBODY; PENTAPEPTIDE; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANGIONEUROTIC EDEMA; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BONE METASTASIS; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CYSTIC FIBROSIS; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; EMPHYSEMA; GENETIC RESISTANCE; GROWTH INHIBITION; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOMODULATION; METASTASIS INHIBITION; MULTIPLE MYELOMA; NONHUMAN; OSTEOPOROSIS; PHARMACODYNAMICS; PROTEIN DOMAIN; PROTEIN ENGINEERING; REVIEW;

ANIMALS; ANTIBODIES; DRUG DISCOVERY; HUMANS; PEPTIDE HYDROLASES; PROTEASE INHIBITORS; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY;

EID: 77956686466     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2010.03.010     Document Type: Review

References (124)

1. López-Otín C., Bond J.S. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283:30433-30437.
2. Rawlings N.D., Morton F.R., Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 2006, 34:D270-D272.
3. Costantino C.M., Ploegh H.L., Hafler D.A. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells. J. Immunol. 2009, 183:945-952.
4. Yan C., Boyd D.D. Regulation of matrix metalloproteinase gene expression. J. Cell Physiol. 2007, 211:19-26.
5. Khan A.R., James M.N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 1998, 7:815-836.
6. Pop C., Salvesen G.S. Human caspases: activation, specificity, and regulation. J. Biol. Chem. 2009, 284:21777-21781.
7. Wiederanders B., Kaulmann G., Schilling K. Functions of propeptide parts in cysteine proteases. Curr. Protein Pept. Sci. 2003, 4:309-326.
8. Ra H.J., Parks W.C. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007, 26:587-596.
9. Allan L.A., Clarke P.R. Apoptosis and autophagy: regulation of caspase-9 by phosphorylation. FEBS J. 2009, 276:6063-6073.
10. Di Cera E. Thrombin. Mol. Aspects Med. 2008, 29:203-254.
11. Eigenbrot C. Structure, function, and activation of coagulation factor VII. Curr. Protein Pept. Sci. 2002, 3:287-299.
12. Cuervo A.M., Dice J.F. Lysosomes, a meeting point of proteins, chaperones, and proteases. J. Mol. Med. 1998, 76:6-12.
13. Korkmaz B., Moreau T., Gauthier F. Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions. Biochimie 2008, 90:227-242.
14. Rawlings N.D., Tolle D.P., Barrett A.J. Evolutionary families of peptidase inhibitors. Biochem. J. 2004, 378:705-716.
15. Turk B., Turk D., Salvesen G.S. Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm Des. 2002, 8:1623-1637.
16. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 2000, 1477:267-283.
17. Dubrez-Daloz L., Dupoux A., Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008, 7:1036-1046.
18. Lee C., Bongcam-Rudloff E., Sollner C., Jahnen-Dechent W., Claesson-Welsh L. Type 3 cystatins; fetuins, kininogen and histidine-rich glycoprotein. Front. Biosci. 2009, 14:2911-2922.
19. Moreau T., Baranger K., Dadé S., Dallet-Choisy S., Guyot N., Zani M.L. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor (SLPI), two serine protease inhibitors of the chelonianin family. Biochimie 2008, 90:284-295.
20. Ascenzi P., Bocedi A., Bolognesi M., Spallarossa A., Coletta M., De Cristofaro R., Menegatti E. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr. Protein Pept. Sci. 2003, 4:231-251.
21. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
22. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
23. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
24. Cudic M., Fields G.B. Extracellular proteases as targets for drug development. Curr. Protein Pept. Sci. 2009, 10:297-307.
25. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin converting enzyme: new class of orally acting active antihypertensive agents. Science 1977, 196:441-444.
26. Abbenante G., Fairlie D.P. Protease inhibitors in the clinic. Med. Chem. 2005, 1:71-104.
27. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 1996, 334:1011-1017.
28. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 1997, 337:734-739.
29. Orlowski R.Z. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev. Anticancer Ther. 2004, 4:171-179.
30. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
31. Falgueyret J.P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., Lamontagne S., Massé F., Riendeau D., Toulmond S., Percival M.D. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 2005, 48:7535-7543.
32. Pirard B. Insight into the structural determinants for selective inhibition of matrix metalloproteinases. Drug Discov. Today 2007, 12:640-646.
33. Black W.C., Percival M.D. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. Chembiochem 2006, 7:1525-1534.
34. Rauber P., Angliker H., Walker B., Shaw E. The synthesis of peptidylfluoromethanes and their properties as inhibitors of serine proteinases and cysteine proteinases. Biochem J. 1986, 239:633-640.
35. Powers J.C., Asgian J.L., Ekici O.D., James K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem Rev. 2002, 102:4639-4750.
36. Rozman-Pungercar J., Kopitar-Jerala N., Bogyo M., Turk D., Vasiljeva O., Stefe I., Vandenabeele P., Brömme D., Puizdar V., Fonović M., Trstenjak-Prebanda M., Dolenc I., Turk V., Turk B. Inhibition of papain-like cysteine proteases and legumain by caspase-specific inhibitors: when reaction mechanism is more important than specificity. Cell Death Differ. 2003, 10:881-888.
37. Link J.O., Zipfel S. Advances in cathepsin S inhibitor design. Curr. Opin. Drug Discov. Develop. 2006, 9:471-482.
38. Waxler B., Rabito S.F. Aprotinin: a serine protease inhibitor with therapeutic actions: its interaction with ACE inhibitors. Curr. Pharm. Des. 2003, 9:777-787.
39. Nixon A.E., Wood C.R. Engineered protein inhibitors of proteases. Curr. Opin. Drug Discov. Develop. 2006, 9:261-268.
40. Markland W., Roberts B.L., Saxena M.J., Guterman S.K., Ladner R.C. Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13. Gene 1991, 109:13-19.
41. Roberts B.L., Markland W., Siranosian K., Saxena M.J., Guterman S.K., Ladner R.C. Protease inhibitor display M13 phage: selection of high-affinity neutrophil elastase inhibitors. Gene 1992, 121:9-15.
42. Roberts B.L., Markland W., Ley A.C., Kent R.B., White D.W., Guterman S.K., Ladner R.C. Directed evolution of a protein: selection of potent neutrophil elastase inhibitors displayed on M13 fusion phage. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:2429-2433.
43. Markland W., Ley A.C., Lee S.W., Ladner R.C. Iterative optimization of high-affinity proteases inhibitors using phage display. 1. Plasmin. Biochemistry 1994, 35:8045-8057.
44. Dennis M.S., Lazarus R.A. Kunitz domain inhibitors of tissue factor - factor VIIa. I. Potent inhibitors selected from libraries by phage display. J. Biol. Chem. 1994, 269:22129-22136.
45. Dennis M.S., Lazarus R.A. Kunitz domain inhibitors of tissue factor - factor VIIa. II. Potent and specific inhibitors by competitive phage selection. J. Biol. Chem. 1994, 269:22137-22144.
46. Markland W., Ley A.C., Ladner R.C. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry 1996, 35:8058-8067.
47. Tosi M. Molecular genetics of C1 inhibitor. Immunobiology 1998, 199:358-365.
48. Davis A.E. The pathophysiology of hereditary angioedema. Clin. Immunol. 2005, 114:3-9.
49. Han Lee E.D., Pappalardo E., Scafidi J., Davis A.E. Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol. Lett. 2003, 89:155-160.
50. Schneider L., Lumry W., Vegh A., Williams A.H., Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J. Allergy Clin. Immunol. 2007, 120:416-422.
51. Hill A.T., Campbell E.J., Bayley D.L., Hill S.L., Stockley R.A. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am. J. Respir. Crit. Care Med. 1999, 160:1968-1975.
52. Piccioni P.D., Kramps J.A., Rudolphus A., Bulgheroni A., Luisetti M. Proteinase/proteinase inhibitor imbalance in sputum sol phases from patients with chronic obstructive pulmonary disease. Suggestions for a key role played by antileukoprotease. Chest 1992, 102:1470-1476.
53. Weldon S., McNally P., McElvaney N.G., Elborn J.S., McAuley D.F., Wartelle J., Belaaouaj A., Levine R.L., Taggart C.C. Decreased levels of secretory leucoprotease inhibitor in the pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J. Immunol. 2009, 183:8148-8156.
54. Geraghty P., Rogan M.P., Greene C.M., Boxio R.M., Poiriert T., O'Mahony M., Belaaouaj A., O'Neill S.J., Taggart C.C., McElvaney N.G. Neutrophil elastase up-regulates cathepsin B and matrix metalloprotease-2 expression. J. Immunol. 2007, 178:5871-5878.
55. Walsh D.E., Greene C.M., Carroll T.P., Taggart C.C., Gallagher P.M., O'Neill S.J., McElvaney N.G. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J. Biol. Chem. 2001, 276:35494-35499.
56. Delacourt C., Hérigault S., Delclaux C., Poncin A., Levame M., Harf A., Saudubray F., Lafuma C. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am. J. Respir. Cell Mol. Biol. 2003, 26:290-297.
57. Saudubray F., Labbe A., Durieu I., Wallaert B., Sayah H., Assael B., Cazzola G., Dubray C., Poncin A., Lafuma C., Williams T., Bokman A., Clavien H. Phase IIa clinical study of a new human neutrophil elastase inhibitor (hNE), EPI-hNE4 (DX-890), with repeated administration by inhalation in adult cystic fibrosis patients. J. Cystic Fibrosis 2003, 2(Suppl. 1):A85.
58. Devy L., Rabbani S.A., Stochl M., Ruskowski M., Mackie I., Naa L., Toews M., van Gool R., Chen J., Ley A., Ladner R.C., Dransfield D.T., Henderikx P. PEGylated DX-1000: pharmacokinetics and antineoplastic activity of a specific plasmin inhibitor. Neoplasia 2007, 9:927-937.
59. Kawe M., Forrer P., Amstutz P., Plückthun A. Isolation of intracellular proteinase inhibitors derived from designed ankyrin repeat proteins by genetic screening. J. Biol. Chem. 2006, 281:40252-40263.
60. Schweizer A., Roschitzki-Voser H., Amstutz P., Briand C., Gulotti-Georgieva M., Prenosil E., Binz H.K., Capitani G., Baici A., Plückthun A., Grütter M.G. Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 2007, 15:625-636.
61. Yang S.Q., Craik C.S. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator. J. Mol. Biol. 1998, 279:1001-1011.
62. Stoop A.A., Craik C.S. Engineering of a macromolecular scaffold to develop specific protease inhibitors. Nat. Biotechnol. 2003, 21:1063-1068.
63. Dimasi N., Martin F., Volpari C., Brunetti M., Biasiol G., Altamura S., Cortese R., De Francesco R., Steinkühler C., Sollazzo M. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol. 1997, 71:7461-7469.
64. Martin F., Dimasi N., Volpari C., Perrera C., Di Marco S., Brunetti M., Steinkühler C., De Francesco R., Sollazzo M. Design of selective eglin inhibitors of HCV NS3 proteinase. Biochemistry 1998, 37:11459-11468.
65. Greene C.M., McElvaney N.G. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br. J. Pharmacol. 2009, 158:1048-1058.
66. Van Molle W., Denecker G., Rodriguez I., Brouckaert P., Vandenabeele P., Libert C. Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins. J. Immunol. 1999, 163:5235-5241.
67. Koulmanda M., Bhasin M., Hoffman L., Fan Z., Qipo A., Shi H., Bonner-Weir S., Putheti P., Degauque N., Libermann T.A., Auchincloss H., Flier J.S., Strom T.B. Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16242-16247.
68. Ranes J., Stoller J.K. A review of alpha-1 antitrypsin deficiency. Semin. Respir. Crit. Care Med. 2005, 26:154-166.
69. Petrache I., Hajjar J., Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics 2009, 3:193-204.
70. Martin S.L., Downey D., Bilton D., Keogan M.T., Edgar J., Elborn J.S. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr. Pulmonol. 2006, 41:177-183.
71. Travis J., Owen M., George P., Carrell R., Rosenberg S., Hallewell R.A., Barr P.J. Isolation and properties of recombinant DNA produced variants of human alpha 1-proteinase inhibitor. J. Biol. Chem. 1985, 260:4384-4389.
72. Taggart C., Cervantes-Laurean D., Kim G., McElvaney N.G., Wehr N., Moss J., Levine R.L. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J. Biol. Chem. 2000, 275:27258-27265.
73. McElvaney N.G., Nakamura H., Birrer P., Hébert C.A., Wong W.L., Alphonso M., Baker J.B., Catalano M.A., Crystal R.G. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest. 1992, 90:1296-1301.
74. Rudolphus A., Heinzel-Wieland R., Vincent V.A., Saunders D., Steffens G.J., Dijkman J.H., Kramps J.A. Oxidation-resistant variants of recombinant antileucoprotease are better inhibitors of human-neutrophil-elastase-induced emphysema in hamsters than natural recombinant antileucoprotease. Clin. Sci. (Lond). 1991, 81:777-784.
75. http://www.proteo.de.
76. Zani M.L., Baranger K., Guyot N., Dallet-Choisy S., Moreau T. Protease inhibitors derived from elafin and SLPI and engineered to have enhanced specificity towards neutrophil serine proteases. Protein Sci. 2009, 18:579-594.
77. Taggart C.C., Lowe G.J., Greene C.M., Mulgrew A.T., O'Neill S.J., Levine R.L., McElvaney N.G. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J. Biol. Chem. 2001, 276:33345-33352.
78. Guyot N., Butler M.W., McNally P., Weldon S., Greene C.M., Levine R.L., O'Neill S.J., Taggart C.C., McElvaney N.G. Elafin, an elastase-specific inhibitor, is cleaved by its cognate enzyme neutrophil elastase in sputum from individuals with cystic fibrosis. J. Biol. Chem. 2008, 283:32377-32385.
79. Mach L., Mort J.S., Glössl J. Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J. Biol. Chem. 1994, 269:13030-13035.
80. Wiederanders B. Structure-function relationships in class CA1 cysteine peptidase propeptides. Acta. Biochim. Pol. 2003, 50:691-713.
81. Carmona E., Dufour E., Plouffe C., Takebe S., Mason P., Mort J.S., Ménard R. Potency and selectivity of the cathepsin L propeptide as an inhibitor of cysteine proteases. Biochemistry 1996, 35:8149-8157.
82. Guay J., Falgueyret J.P., Ducret A., Percival M.D., Mancini J.A. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur. J. Biochem. 2000, 267:6311-6318.
83. Burden R.E., Snoddy P., Jefferies C.A., Walker B., Scott C.J. Inhibition of cathepsin L-like proteases by cathepsin V propeptide. Biol. Chem. 2007, 388:541-545.
84. Fox T., de Miguel E., Mort J.S., Storer A.C. Potent slow-binding inhibition of cathepsin B by its propeptide. Biochemistry 1992, 31:12571-12576.
85. Chagas J.R., Ferrer-Di Martino M., Gauthier F., Lalmanach G. Inhibition of cathepsin B by its propeptide: use of overlapping peptides to identify a critical segment. FEBS Lett. 1996, 392:233-236.
86. Chowdhury S.F., Sivaraman J., Wang J., Devanathan G., Lachance P., Qi H., Ménard R., Lefebvre J., Konishi Y., Cygler M., Sulea T., Purisima E.O. Design of noncovalent inhibitors of human cathepsin L. From the 96-residue proregion to optimized tripeptides. J. Med. Chem. 2002, 45:5321-5329.
87. Burden R.E., Snoddy P., Buick R.J., Johnston J.A., Walker B., Scott C.J. Recombinant cathepsin S propeptide attenuates cell invasion by inhibition of cathepsin L-like proteases in tumor microenvironment. Mol. Cancer Ther. 2008, 7:538-547.
88. Tanaka A.S., Sampaio C.A., Fritz H., E.A Auerswald Functional display and expression of chicken cystatin using a phagemid system. Biochem. Biophys. Res. Commun. 1995, 214:389-395.
89. Melo F.R., Mello M.O., Franco O.L., Rigden D.J., Mello L.V., Genú A.M., Silva-Filho M.C., Gleddie S., Grossi-de-Sá M.F. Use of phage display to select novel cystatins specific for Acanthoscelides obtectus cysteine proteinases. Biochim. Biophys. Acta 2003, 1651:146-152.
90. Reichert J.M. Antibodies to watch in 2010. MAbs 2010, 2. [Epub ahead of print].
91. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
92. Shawler D.L., Bartholomew R.M., Smith L.M., Dillman R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol. 1985, 135:1530-1535.
93. Almagro J.C., Fransson J. Humanization of antibodies. Front. Biosci. 2008, 13:1619-1633.
94. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
95. Dean-Colomb W., Esteva F.J. Her2-positive breast cancer: Herceptin and beyond. Eur. J. Cancer 2008, 44:2806-2812.
96. Margolin K., Gordon M.S., Holmgren E., Gaudreault J., Novotny W., Fyfe G., Adelman D., Stalter S., Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001, 19:851-856.
97. Taylor P.C., Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:578-582.
98. Weber E., Günther D., Laube F., Wiederanders B., Kirschke H. Hybridoma cells producing antibodies to cathepsin L have greatly reduced potential for tumour growth. J. Cancer Res. Clin. Oncol. 1994, 120:564-567.
99. Ganesan R., Eigenbrot C., Wu Y., Liang W.C., Shia S., Lipari M.T., Kirchhofer D. Unraveling the allosteric mechanism of serine protease inhibition by an antibody. Structure 2009, 17:1614-1624.
100. Wu Y., Eigenbrot C., Liang W.C., Stawicki S., Shia S., Fan B., Ganesan R., Lipari M.T., Kirchhofer D. Structural insight into distinct mechanisms of protease inhibition by antibodies. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:19784-19789.
101. Lescar J., Stouracova R., Riottot M.M., Chitarra V., Brynda J., Fabry M., Horejsi M., Sedlacek J., Bentley G.A. Three-dimensional structure of an Fab-peptide complex: structural basis of HIV-1 protease inhibition by a monoclonal antibody. J. Mol. Biol. 1997, 267:1207-1222.
102. Rezacova P., Lescar J., Brynda J., Fabry M., Horejsi M., Sedlacek J., Bentley G.A. Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal antibody. Structure 2001, 9:887-895.
103. Rezacova P., Brynda J., Lescar J., Fabry M., Horejsi M., Sieglova I., Sedlacek J., Bentley G.A. Crystal structure of a cross-reaction complex between an anti-HIV-1 protease antibody and an HIV-2 protease peptide. J. Struct. Biol. 2005, 149:332-337.
104. Rondon I.J., Marasco W.A. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu. Rev. Microbiol. 1997, 51:257-283.
105. Rousselet N., Mills L., Jean D., Tellez C., Bar-Eli M., Frade R. Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. 2004, 64:146-151.
106. Frade R., Rousselet N., Jean D. Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Ther 2008, 15:591-604.
107. Xuan J.A., Schneider D., Toy P., Lin R., Newton A., Zhu Y., Finster S., Vogel D., Mintzer B., Dinter H., Light D., Parry R., Polokoff M., Whitlow M., Wu Q., Parry G. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture. Cancer Res. 2006, 66:3611-3619.
108. List K., Szabo R., Molinolo A., Sriuranpong V., Redeye V., Murdock T., Burke B., Nielsen B.S., Gutkind J.S., Bugge T.H. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev. 2005, 19:1934-1950.
109. Sun J., Pons J., Craik C.S. Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies. Biochemistry 2003, 42:892-900.
110. Farady C.J., Sun J., Darragh M.R., Miller S.M., Craik C.S. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J. Mol. Biol. 2007, 369:1041-1051.
111. Farady C.J., Egea P.F., Schneider E.L., Darragh M.R., Craik C.S. Structure of an Fab-protease complex reveals a highly specific non-canonical mechanism of inhibition. J. Mol. Biol. 2008, 380:351-360.
112. Petersen H.H., Hansen M., Schousboe S.L., Andreasen P.A. Localization of epitopes for monoclonal antibodies to urokinase-type plasminogen activator: relationship between epitope localization and effects of antibodies on molecular interactions of the enzyme. Eur. J. Biochem. 2001, 268:4430-4439.
113. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
114. Mai J., Finley R.L., Waisman D.M., Sloane B.F. Human procathepsin B interacts with the annexin II tetramer on the surface of tumor cells. J. Biol. Chem. 2000, 275:12806-12812.
115. Obermajer N., Premzl A., Zavasnik Bergant T., Turk B., Kos J. Carboxypeptidase cathepsin X mediates beta2-integrin-dependent adhesion of differentiated U-937 cells. Exp. Cell Res. 2006, 312:2515-2527.
116. Premzl A., Zavasnik-Bergant V., Turk V., Kos J. Intracellular and extracellular cathepsin B facilitate invasion of MCF-10A neoT cells through reconstituted extracellular matrix in vitro. Exp. Cell Res. 2003, 283:206-214.
117. Wang B., Sun J., Kitamoto S., Yang M., Grubb A., Chapman H.A., Kalluri R., Shi G.P. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J. Biol. Chem. 2006, 281:6020-6029.
118. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., Hanahan D., Joyce J.A. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20:543-556.
119. Ryschich E., Lizdenis P., Ittrich C., Benner A., Stahl S., Hamann A., Schmidt J., Knolle P., Arnold B., Hämmerling G.J., Ganss R. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res. 2006, 66:198-211.
120. Burden R.E., Gormley J.A., Jaquin T.J., Small D.M., Quinn D.J., Hegarty S.M., Ward C., Walker B., Johnston J.A., Olwill S.A., Scott C.J. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer Res. 2009, 15:6042-6051.
121. Martin F., Volpari C., Steinkuhler C., Dimasi N., Brunetti M., Biasiol G., Altamura S., Cortese R., De Francesco R., Sollazzo M. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng. 1997, 10:607-614.
122. Wassaf D., Kuang G., Kopacz K., Wu Q.L., Nguyen Q., Toews M., Cosic J., Jacques J., Wiltshire S., Lambert J., Pazmany C.C., Hogan S., Ladner R.C., Nixon A.E., Sexton D.J. High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays. Anal. Biochem. 2006, 351:241-253.
123. Sexton D.J., Chen T., Martik D., Kuzmic P., Kuang G., Chen J., Nixon A.E., Zuraw B.L., Forteza R.M., Abraham W.M., Wood C.R. Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. Biochem. J. 2009, 422:383-392.
124. Devy L., Huang L., Naa L., Yanamandra N., Pieters H., Frans N., Chang E., Tao Q., Vanhove M., Lejeune A., van Gool R., Sexton D.J., Kuang G., Rank D., Hogan S., Pazmany C., Ma Y.L., Schoonbroodt S., Nixon A.E., Ladner R.C., Hoet R., Henderikx P., Tenhoor C., Rabbani S.A., Valentino M.L., Wood C.R., Dransfield D.T. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res. 2009, 69:1517-1526.